Project Grant R01HL175166
Award Date
9/29/24
Completion Date
7/31/29
Dollars Obligated
$381K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Clemson, SC 29634, USA
Similar Awards
This $705,405 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the role of adventitial fibroblasts, an understudied cell population, in the development and progression of atherosclerosis. The key objectives are to: Determine the mechanism by which targeted genetic ablation of adventitial fibroblasts decreases atherosclerotic plaque formation, despite these cells not directly contributing to the intimal...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This federal Project Grant award of $1,127,798 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to understand the role of macrophages in preserving cardiovascular health and their contributions to cardiovascular disease (CVD). The overarching goal is to identify new therapeutic targets for CVD in both female and male patients. The research will use advanced single cell imaging and omics techniques to characterize harmful...
This $304,119 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of innovative in vitro 3D atherosclerosis models and high-throughput drug screening assays by Endomimetics LLC. The key objectives are to create an automated, precise approach for fabricating advanced 3D vascular sheet and atherosclerosis models, which will enable efficient, high-throughput testing of drug...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami. The grant supports research to investigate whether extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, and to determine if regulation of the DHCR24 enzyme in myeloid cells impacts limb perfusion, function, and arteriogenesis in peripheral arterial disease. The research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $705,279 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Trustees of Boston University, doing business as Boston University Medical Campus, to investigate the mechanisms by which environmental pollutants impact the cardiovascular system. The 4-year project, starting January 1, 2025, will use a multidisciplinary approach including physiological studies, cellular imaging, RNA-sequencing, and mouse models to...
This Project Grant award of $646,106 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Tulane University to determine whether the induction of RECK, a regulator of proteinases, can prevent the development and progression of atherosclerosis. The research aims to 1) evaluate if RECK overexpression in smooth muscle cells attenuates atherosclerosis progression and promotes plaque stability, 2) study if RECK overexpression in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $686,640 to The Trustees of Columbia University in the City of New York, Health Sciences Division, to conduct research focused on enhancing macrophage efferocytosis as a potential therapeutic strategy for atherosclerotic cardiovascular disease (ACVD). The key objectives are to: 1) Determine how knocking out the ILRUN gene can enhance...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $874,792 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center (VUMC). The award, effective July 15, 2024 through June 30, 2028, will support research to: (1) identify new genetic variants associated with residual atherosclerotic cardiovascular disease (ASCVD) risk in patients on treatment to lower LDL-cholesterol...